PMID- 21979834
OWN - NLM
STAT- MEDLINE
DCOM- 20130205
LR  - 20211020
IS  - 1473-5849 (Electronic)
IS  - 0955-8810 (Linking)
VI  - 22
IP  - 8
DP  - 2011 Dec
TI  - Behavioral sensitization to 3,4-methylenedioxymethamphetamine is long-lasting and 
      modulated by the context of drug administration.
PG  - 847-50
LID - 10.1097/FBP.0b013e32834d13b4 [doi]
AB  - To begin to characterize the temporal profile of behavioral sensitization to the 
      amphetamine derivative 3,4-methylenedioxymethamphetamine (MDMA), rats were 
      treated with either saline or MDMA (5.0 mg/kg) twice daily for 5 days, followed 
      by a challenge injection of MDMA (2.5 mg/kg) either 15 or 100 days later. Because 
      we found previously that contextual drug associations are important for the 
      expression of behavioral sensitization to MDMA following relatively short 
      withdrawal periods, rats received the repeated injections either in their home 
      cages (unpaired group) or in the activity monitors that were used for testing 
      sensitization on challenge day (paired group). Locomotor sensitization was 
      evident at 15 days of withdrawal but only in the paired MDMA-treated group. 
      Interestingly, however, sensitization was apparent at 100 days of withdrawal in 
      both paired and unpaired rats but the form of sensitization differed between 
      groups. Thus, sensitization in paired rats was expressed as an increase in 
      stereotypy, whereas sensitization in unpaired rats was expressed as an increase 
      in locomotion, paralleling locomotion levels in paired animals at 15 days of 
      withdrawal. These results suggest that the neural changes that underlie 
      behavioral sensitization to MDMA are quite enduring but involve an interaction 
      between withdrawal time and the context of drug administration.
FAU - Ball, Kevin T
AU  - Ball KT
AD  - Department of Psychology, Bloomsburg University of Pennsylvania, Bloomsburg, 
      Pennsylvania 17815, USA. kball@bloomu.edu
FAU - Klein, Jessalyn E
AU  - Klein JE
FAU - Plocinski, Jacob A
AU  - Plocinski JA
FAU - Slack, Rachel
AU  - Slack R
LA  - eng
GR  - R15 DA035432/DA/NIDA NIH HHS/United States
GR  - R03 DA027960-02/DA/NIDA NIH HHS/United States
GR  - DA027960/DA/NIDA NIH HHS/United States
GR  - R03 DA027960-01/DA/NIDA NIH HHS/United States
GR  - R03 DA027960/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Behav Pharmacol
JT  - Behavioural pharmacology
JID - 9013016
RN  - 0 (Hallucinogens)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Behavior, Animal/*drug effects
MH  - Hallucinogens/administration & dosage/*pharmacology
MH  - Male
MH  - Motor Activity/*drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
PMC - PMC3212638
MID - NIHMS331898
EDAT- 2011/10/08 06:00
MHDA- 2013/02/06 06:00
CRDT- 2011/10/08 06:00
PHST- 2011/10/08 06:00 [entrez]
PHST- 2011/10/08 06:00 [pubmed]
PHST- 2013/02/06 06:00 [medline]
AID - 10.1097/FBP.0b013e32834d13b4 [doi]
PST - ppublish
SO  - Behav Pharmacol. 2011 Dec;22(8):847-50. doi: 10.1097/FBP.0b013e32834d13b4.